The latest update is out from HUTCHMED (China) Limited ( (HK:0013) ).
HUTCHMED (China) Limited has announced the disposal of a 45% equity interest in Shanghai Hutchison Pharmaceuticals Limited (SHPL). The transaction involves selling 35% of SHPL to GP Health Service Capital and 10% to Shanghai Pharma. This strategic move is structured through various agreements, including the GP Health SPA and Shanghai Pharma SPA, with designated purchasers acquiring specific equity interests. The sale is valued at approximately RMB2.5 billion for a portion of the shares, reflecting a calculated valuation based on SHPL’s net profit. This disposal is expected to impact HUTCHMED’s financial structure and market positioning, potentially providing liquidity and focusing resources on core operations.
More about HUTCHMED (China) Limited
HUTCHMED (China) Limited is a biopharmaceutical company focused on the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company operates primarily in China and is involved in the pharmaceutical industry, with a significant emphasis on innovative drug development.
YTD Price Performance: 13.19%
Average Trading Volume: 52,646
Technical Sentiment Consensus Rating: Hold
Current Market Cap: £2.29B
Find detailed analytics on 0013 stock on TipRanks’ Stock Analysis page.